Abstract
Bladder Cancer (BC) is among the most prevalent malignancies globally, and the number of new BC cases is expected to increase. The muscle-invasive form of BC is particularly aggressive and often lethal. Conventional treatment options for BC include nontargeted chemotherapy, vaccination-based immunotherapy, and surgical interventions, which may involve complete removal of the bladder. Many patients develop resistance to conventional chemotherapies and immunotherapies and experience significant side effects, leading to poor clinical outcomes. Recent advancements in molecular biology and biotechnology are changing the landscape of BC treatment. This review evaluates whether novel targeted and nontargeted therapies can alleviate toxicity, minimize side effects, and prevent resistance associated with conventional treatments for BC. Furthermore, an overview of the molecular classification system for BC is provided, emphasizing its advantages over traditional histopathological classification. We survey the current diagnostic landscape, from cystoscopy, TURBT-based tissue analysis, and urine cytology to protein-based urinary tests, circulating tumor DNA, and emerging biosensor platforms for minimally invasive point-of-care testing, and we consider how these modalities differ in sensitivity, invasiveness, and resource requirements. The potential impact of new diagnostic markers and preclinical models on BC treatment protocols is further discussed. Finally, this review summarizes the growing understanding of the role of ferroptosis in BC, highlighting its potential as a novel avenue for treatment development. In conclusion, it is asserted that innovative treatment strategies, improved diagnostic markers, advanced preclinical models, and deeper insights into the molecular foundations of BC can significantly improve clinical outcomes for a broad spectrum of BC patients.